A biological target is anything within a living organism to which some other entity (like an endogenous ligand or a drug) is directed and/or binds, resulting in a change in its behavior or function. Examples of common classes of biological targets are proteins and nucleic acids. The definition is context-dependent, and can refer to the biological target of a pharmacologically active drug compound, the receptor target of a hormone (like insulin), or some other target of an external stimulus. Biological targets are most commonly proteins such as enzymes, ion channels, and receptors.
- noncovalent – A relatively weak interaction between the stimulus and the target where no chemical bond is formed between the two interacting partners and hence the interaction is completely reversible.
- reversible covalent - A chemical reaction occurs between the stimulus and target in which the stimulus becomes chemically bonded to the target, but the reverse reaction also readily occurs in which the bond can be broken.
- irreversible covalent - The stimulus is permanently bound to the target through irreversible chemical bond formation.
- There is no direct change in the biological target, but the binding of the substance prevents other endogenous substances (such as activating hormones) from binding to the target. Depending on the nature of the target, this effect is referred as receptor antagonism, enzyme inhibition, or ion channel blockade.
- A conformational change in the target is induced by the stimulus which results in a change in target function. This change in function can mimic the effect of the endogenous substance in which case the effect is referred to as receptor agonism (or channel or enzyme activation) or be the opposite of the endogenous substance which in the case of receptors is referred to as inverse agonism.
The term "biological target" is frequently used in pharmaceutical research to describe the native protein in the body whose activity is modified by a drug resulting in a specific effect, which may be a desirable therapeutic effect or an unwanted adverse effect. In this context, the biological target is often referred to as a drug target. The most common drug targets of currently marketed drugs include:
- nucleic acids
Drug target identification
Identifying the biological origin of a disease, and the potential targets for intervention, is the first step in the discovery of a medicine. This has been a great challenge for both academia and industry. Number of different approaches and technologies are reviewed.
Databases containing biological targets information:
- Raffa RB, Porreca F (1989). "Thermodynamic analysis of the drug-receptor interaction". Life Sci. 44 (4): 245–58. doi:10.1016/0024-3205(89)90182-3. PMID 2536880.
- Moy VT, Florin EL, Gaub HE (1994). "Intermolecular forces and energies between ligands and receptors". Science. 266 (5183): 257–9. doi:10.1126/science.7939660. PMID 7939660.
- Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G (2012). "Chapter 3: How drugs act: molecular aspects". Rang and Dale's Pharmacology. Edinburgh; New York: Elsevier/Churchill Livingstone. pp. 20–48. ISBN 0-7020-3471-1.
- Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G (2012). "Chapter 2: How drugs act: general principles". Rang and Dale's Pharmacology. Edinburgh; New York: Elsevier/Churchill Livingstone. pp. 6–19. ISBN 0-7020-3471-1.
- Overington JP, Al-Lazikani B, Hopkins AL (2006). "How many drug targets are there?". Nat Rev Drug Discov. 5 (12): 993–6. doi:10.1038/nrd2199. PMID 17139284.
- Landry Y, Gies JP (2008). "Drugs and their molecular targets: an updated overview". Fundam Clin Pharmacol. 22 (1): 1–18. doi:10.1111/j.1472-8206.2007.00548.x. PMID 18251718.
- Lundstrom K (2009). "An overview on GPCRs and drug discovery: structure-based drug design and structural biology on GPCRs". Methods Mol. Biol. 552: 51–66. doi:10.1007/978-1-60327-317-6_4. PMID 19513641.
- Lomenick, Brett; Olsen, Richard W.; Huang, Jing (21 January 2011). "Identification of Direct Protein Targets of Small Molecules". ACS Chemical Biology. 6 (1): 34–46. doi:10.1021/cb100294v.